36647-85-5 Usage
General Description
2,2-dioxido-6,15-dioxo-3-oxa-2lambda~6~-thia-7,14-diazaheptadecan-17-yl methanesulfonate is a chemical compound that belongs to the class of sulfonate esters. It is a synthetic organic compound with a complex structure that contains multiple oxygen, sulfur, nitrogen, and carbon atoms. The presence of the methanesulfonate group indicates that it is a derivative of methanesulfonic acid. 2,2-dioxido-6,15-dioxo-3-oxa-2lambda~6~-thia-7,14-diazaheptadecan-17-yl methanesulfonate may have potential applications in various fields including pharmaceuticals, agrochemicals, and materials science due to its unique structure and properties. It is likely to have specific functions or reactivity related to its molecular structure, and further research and analysis would be required to fully understand its potential uses and implications.
Check Digit Verification of cas no
The CAS Registry Mumber 36647-85-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,6,4 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 36647-85:
(7*3)+(6*6)+(5*6)+(4*4)+(3*7)+(2*8)+(1*5)=145
145 % 10 = 5
So 36647-85-5 is a valid CAS Registry Number.
36647-85-5Relevant articles and documents
Novel Bis-sulfonic Acid Esters with Cytostatic Activity (author's transl)
Senning,Buchholt,Bierling
, p. 1800 - 1809 (2007/10/05)
The introduction of electron-withdrawing groups into the group R of piposulfan analogs R--SO2--O--X--O--SO2--R substantially increases their antileukemic activity in animal tests (leukemia L 1210). The central moiety X can be varied considerably (provided it contains amide groups) without appreciable loss of activity. A number of busulfan analogs as well as busulfan itself proved to be practically inactive against murine leukemia L 1210. Among a total of 122 bis-sulfonic acid esters tested 35 gave a survival time index of 150% or more after i.p. application and 5 after oral application.